Weight Loss Injections in India: What UK Patients Need to Know About Semaglutide in 2026

The GLP-1 revolution has transformed weight management more profoundly than anything that has come before it in decades. Semaglutide -- sold under brand names Ozempic, Wegovy, and Rybelsus -- produces clinically significant weight loss that diet and exercise alone rarely achieve, particularly for patients struggling with hormonally driven or metabolically resistant fat accumulation.

But in the UK, access to semaglutide is deeply unequal. NHS criteria are strict, waiting lists stretch to two years, and private prescriptions carry a cost that many professionals find difficult to justify long-term. Since 2022, persistent supply shortages have compounded the problem, leaving even private patients without medication for months at a time.

A growing number of UK patients are now exploring supervised semaglutide programmes in India -- structured, medically overseen courses that cost a fraction of UK private pricing, delivered by endocrinologists and metabolic medicine specialists at JCI-accredited facilities. This article explains what that looks like, who it suits, and what to get right.

What Semaglutide Actually Does

Semaglutide is a GLP-1 receptor agonist -- a synthetic version of a hormone your gut naturally produces after eating. It works through several complementary mechanisms that make it categorically different from previous weight management medications.

• It slows gastric emptying, which means food moves more slowly from the stomach into the small intestine -- keeping you feeling full for longer after a meal.
• It increases satiety signals sent to the brain, specifically to the hypothalamus, reducing appetite and food-seeking behaviour at a neurological level.
• It reduces cravings and the reward response to high-calorie foods, which many patients describe as the most transformative effect.
• It was originally developed and approved for type 2 diabetes management, where it also reduces cardiovascular risk. Weight management approval followed clinical trial evidence showing 15-20% average body weight reduction over 68 weeks.
• Patients with a BMI of 27-29 -- overweight but not clinically obese -- are categorically excluded regardless of how significantly their weight affects their health, confidence, or quality of life.
• Private prescriptions are available but carry a significant cost: £200-£400 per month for ongoing medication, plus consultation fees. Over 12 months, that is £2,400-£4,800 for medication alone.
• UK pharmacy supply of Wegovy and Ozempic has been consistently disrupted from 2022 through 2026. Many private patients have faced gaps of 4-8 weeks without medication due to shortages -- which causes weight regain and undermines the programme.
• Full medical consultation with an endocrinologist or bariatric medicine specialist.
• Blood panel: HbA1c, fasting glucose, lipid profile, liver function, thyroid panel, full metabolic screen.
• Cardiovascular risk assessment and review of current medications for contraindications.
• Realistic discussion of expected outcomes based on your individual metabolic profile.
• Start at 0.25mg weekly -- the standard introductory dose that minimises side effects.
• Titrate upward over 16-20 weeks to the therapeutic maintenance dose (typically 1-2.4mg weekly).
• Dose increases are guided by tolerance, not a fixed schedule. Patients who experience significant nausea hold at their current dose.
• Monthly remote consultations with the prescribing doctor via video call -- included in the programme.
• Dietary guidance and macronutrient targets tailored to the semaglutide protocol.
• Blood monitoring at 3 and 6 months to track metabolic response.
• Minimum programme duration: 6 months. Optimal: 12 months for sustained results and adaptation.
• Cost in Delhi: £80-£150 per month, all-inclusive (medication, consultations, monitoring).
• Equivalent UK private cost: £200-£400 per month for medication alone, plus separate consultation fees.
• BMI 27 or above with at least one weight-related concern (blood pressure, prediabetes, joint strain, elevated cardiovascular risk, or significant impact on quality of life).
• No current medications that significantly interact with GLP-1 receptor agonists.
• Willing to engage with dietary modification alongside the injection programme.
• Prepared to commit to a minimum 12-month programme for durable results.
• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) -- a real contraindication, not precautionary.
• Current or recent pancreatitis.
• Pregnancy or planned pregnancy during the treatment window.
• Patients looking for a short-term fix before an event -- this is not how semaglutide works, and short courses without structured tapering cause rapid weight regain.
• Prescribing doctors are endocrinologists or bariatric medicine specialists -- not general practitioners.
• Dosing protocols follow UK and European clinical guidelines (NICE, ECPO), not local variations.
• Blood monitoring is included and structured -- it is not an optional add-on.
• The medication dispensed is genuine branded semaglutide from licensed pharmaceutical manufacturers -- not compounded, not generic, not unregulated versions sourced from unverified suppliers. This distinction is important: the UK market has seen a rise in unregulated compounded semaglutide sold online that carries real safety risks.
• Medical records are managed to GDPR-compliant standards and are available to your UK GP on request.
• Remote follow-up is designed for UK-based patients -- all ongoing supervision is via video consultation.
• CoolSculpting addresses isolated subcutaneous fat pockets that persist after weight loss -- particularly the lower abdomen, flanks, and inner thighs.
• HIFU and Morpheus8 address skin laxity -- the loose, crepey skin that can develop when significant weight is lost faster than skin can adapt.
• EMSculpt Neo addresses muscle tone -- many patients emerging from a semaglutide programme want to rebuild or improve muscle definition alongside fat reduction.
• Stopping semaglutide abruptly -- without tapering and without establishing sustainable dietary habits -- almost universally results in significant weight regain. Studies show most patients regain 50-70% of lost weight within 12 months of stopping.
• The minimum commitment for durable results is 12 months. Many patients remain on maintenance doses beyond that.
• Nausea is common at dose increases and typically resolves within 1-2 weeks of stabilising at each new dose. Managing meal timing and portion size helps significantly.
• Rare but serious risks include pancreatitis. This is why a thorough initial assessment and ongoing monitoring are non-negotiable, not optional extras.
• Muscle mass loss can occur alongside fat loss if protein intake is insufficient. The dietary guidance in the programme addresses this specifically.

This is not a quick fix and it is not a cosmetic procedure. Semaglutide works most effectively when combined with dietary modification and structured lifestyle changes -- the medication reduces appetite, but what patients eat still matters. Programmes that treat it as a simple injection and nothing more produce inferior results.

The UK Access Problem

The NHS prescribes semaglutide for weight management only under specific criteria: a BMI above 35 with at least one weight-related comorbidity, or a BMI above 30 with at least one qualifying condition. Patients meeting these thresholds must be referred to a specialist Tier 3 weight management service -- and the current wait for that referral typically runs to 18-24 months.

The result is that a large group of patients who are good clinical candidates for semaglutide -- those with BMIs in the 27-35 range, or those who can afford medication but not ongoing UK private fees -- are effectively excluded from a treatment that could genuinely help them.

What a Medical Weight Loss Programme with Semaglutide Looks Like in Delhi

Incostra's partner clinics offer semaglutide as part of a structured, medically supervised weight loss programme -- not as a standalone prescription. The distinction matters. A prescription without monitoring is a risk. A programme with clinical oversight is a tool.

Initial Assessment

Dosing Protocol

Ongoing Supervision

Programme Duration and Cost

Who Is Suitable -- and Who Is Not

Semaglutide is a medical treatment with genuine contraindications, not a cosmetic procedure available to anyone who wants it. Incostra will not prescribe it without a clinical assessment, and the assessment will disqualify some patients.

Generally Suitable

Not Suitable

Safety and Medical Oversight in India

A reasonable concern for any patient considering treatment abroad is whether clinical standards are comparable. In the case of semaglutide at Incostra's partner clinics, the answer is that the oversight is equivalent to and in some respects more thorough than typical UK private prescribing.

Combining Semaglutide with Body Contouring

A pattern Incostra increasingly sees is patients who use semaglutide for 6-12 months to achieve significant weight reduction, and then travel to Delhi to address what remains. Weight loss of 15-20% is clinically impressive -- but it can leave behind stubborn fat pockets that dietary restriction alone did not touch, and skin that has not retracted at the pace of the underlying fat loss.

Incostra offers combined medical weight loss and body contouring programmes. The weight loss phase is managed remotely from the UK; the contouring phase involves a 3-5 day trip to Delhi when the patient has reached their target weight and the clinical picture suits treatment.

Important Considerations -- What to Get Right

Semaglutide works. But it works within a framework of realistic expectations and proper management. These are the things patients most commonly underestimate.

Duration and Continuity

Side Effects

Assessment Is Mandatory

Incostra does not prescribe semaglutide without a medical assessment. If an assessment finds that you are not a suitable candidate, you will be told plainly and the reasons explained. We treat this as a feature of the programme, not a barrier.